Walgreens Boots Alliance, Inc.

Case Overview
38 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 03/31/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Walgreens Boots Alliance, Inc. |
Court: | Court: Northern District of Illinois |
Case Number: | Case Number: 1:25cv01058 |
Class Period: | Class Period: 04/02/2020 - 01/16/2025 |
Ticker: | Ticker: WBA |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of Illinois on behalf of those who acquired Walgreens Boots Alliance, Inc. (“Walgreens” or the “Company”) (NASDAQ:WBA) securities during the period from April 2, 2020, through January 16, 2025 (“the Class Period”). Investors have until March 31, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On January 17, 2025, the DOJ announced the filing of a civil complaint alleging that Walgreens “dispensed millions of unlawful prescriptions in violation of the Controlled Substance Act (CSA) and then sought reimbursement for many of these prescriptions from various federal health care programs in violation of the False Claims Act (FCA).” Specifically, the complaint alleged that, from approximately August 2012 through the present, Walgreens knowingly filled millions of prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice”, including “prescriptions for dangerous and excessive quantities of opioids, prescriptions for early refills of opioids and prescriptions for the especially dangerous and abused combination of drugs known as the trinity.” In addition, the complaint expressly alleged that Walgreens was “aware of its obligation to exercise corresponding responsibility” and that its business practices were at odds with earlier commitments to “implement or maintain a variety of compliance measures moving forward.” On this news, the price of Walgreens shares declined by $1.56 per share, from $12.52 per share on January 17, 2025, to close at $11.37 on January 21, 2025.
The lawsuit alleges that defendants, throughout the Class Period, made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; and (2) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm.
On January 17, 2025, the DOJ announced the filing of a civil complaint alleging that Walgreens “dispensed millions of unlawful prescriptions in violation of the Controlled Substance Act (CSA) and then sought reimbursement for many of these prescriptions from various federal health care programs in violation of the False Claims Act (FCA).” Specifically, the complaint alleged that, from approximately August 2012 through the present, Walgreens knowingly filled millions of prescriptions for controlled substances that lacked a legitimate medical purpose, were not valid, and/or were not issued in the usual course of professional practice”, including “prescriptions for dangerous and excessive quantities of opioids, prescriptions for early refills of opioids and prescriptions for the especially dangerous and abused combination of drugs known as the trinity.” In addition, the complaint expressly alleged that Walgreens was “aware of its obligation to exercise corresponding responsibility” and that its business practices were at odds with earlier commitments to “implement or maintain a variety of compliance measures moving forward.” On this news, the price of Walgreens shares declined by $1.56 per share, from $12.52 per share on January 17, 2025, to close at $11.37 on January 21, 2025.
The lawsuit alleges that defendants, throughout the Class Period, made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to the Company’s purported commitment to improved regulatory compliance, Walgreens continued to engage in widespread violations of federal law governing the dispensation of prescription medication and reimbursement for the same; and (2) the foregoing conduct, when revealed, would subject Walgreens to a heightened risk of further regulatory scrutiny, civil liability, and reputational harm.